CVVT showcased R&D achievement at Asia Summit on Global Health

Our research team participated in the Asia Summit on Global Health (ASGH) jointly organised by the HKSAR Government and the Hong Kong Trade Development Council on May 17 & 18, 2023, and showcased major R&D achievements in vaccinology and stem cell technology for disease modelling.​

PD-1 based DNA vaccine is one of the next generation vaccines we are prototyping for cancer immunotherapy. Animal studies showed that the vaccine exhibited both prophylactic and therapeutic efficacies. In addition, we have established the first complete human respiratory organoid culture system which can efficiently reconstruct and reproducibly expand the entire human respiratory epithelium in culture plates using the patented formulation and strategy. These organoids represent biological relevant and universal tools for diverse biomedical and pharmaceutical applications, such as disease modelling, toxicological evaluation, development of therapeutics, and personalized medicine.​

The Centre for Virology, Vaccinology and Therapeutics (CVVT) is a pioneering biotech R&D Centre at HKSTP helmed by renowned HKU microbiology researchers and overseas collaborators. CVVT is funded by the ITC's InnoHK programme to develop novel vaccines and therapeutics against emerging infectious diseases. 

Click HERE to learn more about ASGH.

More information about CVVT’s innovations: https://www.cvvt.hk/ourtechnology